Using oncolytic viruses to ignite the tumour immune microenvironment in bladder cancer
Published 2021 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Using oncolytic viruses to ignite the tumour immune microenvironment in bladder cancer
Authors
Keywords
-
Journal
Nature Reviews Urology
Volume 18, Issue 9, Pages 543-555
Publisher
Springer Science and Business Media LLC
Online
2021-06-29
DOI
10.1038/s41585-021-00483-z
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Systematic Review of the Therapeutic Efficacy of Bladder-preserving Treatments for Non–muscle-invasive Bladder Cancer Following Intravesical Bacillus Calmette-Guérin
- (2020) Roger Li et al. EUROPEAN UROLOGY
- Atezolizumab with or without chemotherapy in metastatic urothelial cancer (IMvigor130): a multicentre, randomised, placebo-controlled phase 3 trial
- (2020) Matthew D Galsky et al. LANCET
- Type I interferon induces CXCL13 to support ectopic germinal center formation
- (2019) Alice E. Denton et al. JOURNAL OF EXPERIMENTAL MEDICINE
- Nivolumab Alone and With Ipilimumab in Previously Treated Metastatic Urothelial Carcinoma: CheckMate 032 Nivolumab 1 mg/kg Plus Ipilimumab 3 mg/kg Expansion Cohort Results
- (2019) Padmanee Sharma et al. JOURNAL OF CLINICAL ONCOLOGY
- Viral targeting of non-muscle invasive bladder cancer and priming of anti-tumour immunity following intravesical Coxsackievirus A21
- (2019) Nicola E Annels et al. CLINICAL CANCER RESEARCH
- Optimizing oncolytic virotherapy in cancer treatment
- (2019) Kevin Harrington et al. NATURE REVIEWS DRUG DISCOVERY
- Clinical efficacy and biomarker analysis of neoadjuvant atezolizumab in operable urothelial carcinoma in the ABACUS trial
- (2019) Thomas Powles et al. NATURE MEDICINE
- Antitumor Activity and Treatment-Related Toxicity Associated With Nivolumab Plus Ipilimumab in Advanced Malignancies: A Systematic Review and Meta-Analysis
- (2019) Hang Xu et al. Frontiers in Pharmacology
- Predicting Response to Intravesical Bacillus Calmette-Guérin Immunotherapy: Are We There Yet? A Systematic Review
- (2018) Ashish M. Kamat et al. EUROPEAN UROLOGY
- The oncolytic Adenovirus XVir-N-31 as a novel therapy in muscle-invasive bladder cancer
- (2018) Eva Lichtenegger et al. HUMAN GENE THERAPY
- PD-L1 in tumor microenvironment mediates resistance to oncolytic immunotherapy
- (2018) Dmitriy Zamarin et al. JOURNAL OF CLINICAL INVESTIGATION
- Randomized, Open-Label Phase II Study Evaluating the Efficacy and Safety of Talimogene Laherparepvec in Combination With Ipilimumab Versus Ipilimumab Alone in Patients With Advanced, Unresectable Melanoma
- (2018) Jason Chesney et al. JOURNAL OF CLINICAL ONCOLOGY
- Neoadjuvant oncolytic virotherapy before surgery sensitizes triple-negative breast cancer to immune checkpoint therapy
- (2018) Marie-Claude Bourgeois-Daigneault et al. Science Translational Medicine
- Intravenous injections of the oncolytic virus M1 as a novel therapy for muscle-invasive bladder cancer
- (2018) Cheng Hu et al. Cell Death & Disease
- Oncolytic Immunotherapy for Bladder Cancer Using Coxsackie A21 Virus
- (2018) Nicola E. Annels et al. Molecular Therapy-Oncolytics
- TGFβ attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells
- (2018) Sanjeev Mariathasan et al. NATURE
- Pembrolizumab as Neoadjuvant Therapy Before Radical Cystectomy in Patients With Muscle-Invasive Urothelial Bladder Carcinoma (PURE-01): An Open-Label, Single-Arm, Phase II Study
- (2018) Andrea Necchi et al. JOURNAL OF CLINICAL ONCOLOGY
- Immune Checkpoint Blockade in Metastatic Urothelial Cancer
- (2017) Arjun Vasant Balar JOURNAL OF CLINICAL ONCOLOGY
- An open label, single-arm, phase II multicenter study of the safety and efficacy of CG0070 oncolytic vector regimen in patients with BCG-unresponsive non–muscle-invasive bladder cancer: Interim results
- (2017) Vignesh T. Packiam et al. UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS
- In situ click chemistry generation of cyclooxygenase-2 inhibitors
- (2017) Atul Bhardwaj et al. Nature Communications
- Comprehensive Transcriptional Analysis of Early-Stage Urothelial Carcinoma
- (2016) Jakob Hedegaard et al. CANCER CELL
- Recurrent Loss of STING Signaling in Melanoma Correlates with Susceptibility to Viral Oncolysis
- (2016) Tianli Xia et al. CANCER RESEARCH
- The Efficacy of Oncolytic Adenovirus Is Mediated by T-cell Responses against Virus and Tumor in Syrian Hamster Model
- (2016) Xiaozhu Li et al. CLINICAL CANCER RESEARCH
- Talimogene Laherparepvec in Combination With Ipilimumab in Previously Untreated, Unresectable Stage IIIB-IV Melanoma
- (2016) Igor Puzanov et al. JOURNAL OF CLINICAL ONCOLOGY
- Definitions, End Points, and Clinical Trial Designs for Non–Muscle-Invasive Bladder Cancer: Recommendations From the International Bladder Cancer Group
- (2016) Ashish M. Kamat et al. JOURNAL OF CLINICAL ONCOLOGY
- Combination Therapy With Reovirus and Anti-PD-1 Blockade Controls Tumor Growth Through Innate and Adaptive Immune Responses
- (2016) Karishma Rajani et al. MOLECULAR THERAPY
- Mutations Associated with Acquired Resistance to PD-1 Blockade in Melanoma
- (2016) Jesse M. Zaretsky et al. NEW ENGLAND JOURNAL OF MEDICINE
- Oncolytic herpes simplex virus interactions with the host immune system
- (2016) Dipongkor Saha et al. Current Opinion in Virology
- Defining Effective Combinations of Immune Checkpoint Blockade and Oncolytic Virotherapy
- (2015) J. J. Rojas et al. CLINICAL CANCER RESEARCH
- Immunogenic cell death
- (2015) Abhishek D. Garg et al. INTERNATIONAL JOURNAL OF DEVELOPMENTAL BIOLOGY
- Talimogene Laherparepvec Improves Durable Response Rate in Patients With Advanced Melanoma
- (2015) Robert H.I. Andtbacka et al. JOURNAL OF CLINICAL ONCOLOGY
- Distinct germinal center selection at local sites shapes memory B cell response to viral escape
- (2015) Yu Adachi et al. JOURNAL OF EXPERIMENTAL MEDICINE
- Viral Infection of Tumors Overcomes Resistance to PD-1-immunotherapy by Broadening Neoantigenome-directed T-cell Responses
- (2015) Norman Woller et al. MOLECULAR THERAPY
- RIG-I in RNA virus recognition
- (2015) Alison M. Kell et al. VIROLOGY
- Identification of Distinct Basal and Luminal Subtypes of Muscle-Invasive Bladder Cancer with Different Sensitivities to Frontline Chemotherapy
- (2014) Woonyoung Choi et al. CANCER CELL
- Molecular Pathways: The Immunogenic Effects of Platinum-Based Chemotherapeutics
- (2014) S. V. Hato et al. CLINICAL CANCER RESEARCH
- The cGAS-cGAMP-STING Pathway of Cytosolic DNA Sensing and Signaling
- (2014) Xin Cai et al. MOLECULAR CELL
- Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients
- (2014) Roy S. Herbst et al. NATURE
- PD-1 blockade induces responses by inhibiting adaptive immune resistance
- (2014) Paul C. Tumeh et al. NATURE
- Intrinsic subtypes of high-grade bladder cancer reflect the hallmarks of breast cancer biology
- (2014) J. S. Damrauer et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Consensus guidelines for the detection of immunogenic cell death
- (2014) Oliver Kepp et al. OncoImmunology
- Signatures of mutational processes in human cancer
- (2013) Ludmil B. Alexandrov et al. NATURE
- Combination of a fusogenic glycoprotein, pro-drug activation and oncolytic HSV as an intravesical therapy for superficial bladder cancer
- (2012) G R Simpson et al. BRITISH JOURNAL OF CANCER
- A First in Human Phase 1 Study of CG0070, a GM-CSF Expressing Oncolytic Adenovirus, for the Treatment of Nonmuscle Invasive Bladder Cancer
- (2012) James M. Burke et al. JOURNAL OF UROLOGY
- Effective Treatment of an Orthotopic Xenograft Model of Human Glioblastoma Using an EGFR-retargeted Oncolytic Herpes Simplex Virus
- (2012) Hiroaki Uchida et al. MOLECULAR THERAPY
- Oncolytic virotherapy
- (2012) Stephen J Russell et al. NATURE BIOTECHNOLOGY
- Targeting Tumor Vasculature With an Oncolytic Virus
- (2011) Caroline J Breitbach et al. MOLECULAR THERAPY
- Herpes virus oncolytic therapy reverses tumor immune dysfunction and facilitates tumor antigen presentation
- (2010) Fabian Benencia et al. CANCER BIOLOGY & THERAPY
- A Viral Vaccine Encoding Prostate-Specific Antigen Induces Antigen Spreading to a Common Set of Self-Proteins in Prostate Cancer Patients
- (2010) N. J. Nesslinger et al. CLINICAL CANCER RESEARCH
- PD-1 and CTLA-4 combination blockade expands infiltrating T cells and reduces regulatory T and myeloid cells within B16 melanoma tumors
- (2010) M. A. Curran et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Local and Distant Immunity Induced by Intralesional Vaccination with an Oncolytic Herpes Virus Encoding GM-CSF in Patients with Stage IIIc and IV Melanoma
- (2009) Howard L. Kaufman et al. ANNALS OF SURGICAL ONCOLOGY
- T Cell Activation
- (2009) Jennifer E. Smith-Garvin et al. Annual Review of Immunology
- Defining Early Morbidity of Radical Cystectomy for Patients with Bladder Cancer Using a Standardized Reporting Methodology
- (2008) Ahmad Shabsigh et al. EUROPEAN UROLOGY
- A let-7 MicroRNA-sensitive Vesicular Stomatitis Virus Demonstrates Tumor-specific Replication
- (2008) Robert E Edge et al. MOLECULAR THERAPY
- Protein kinase R reveals an evolutionary model for defeating viral mimicry
- (2008) Nels C. Elde et al. NATURE
- Chemical targeting of the innate antiviral response by histone deacetylase inhibitors renders refractory cancers sensitive to viral oncolysis
- (2008) T. L.-A. Nguyen et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started